Death (any cause) · people with CKD who are overweight or obese
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · people with CKD who are overweight or obese
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ weight loss · people with CKD who are overweight or obese
1 finding from 1 review
Body‐mass index (BMI) · people with CKD who are overweight or obese
1 finding from 1 review
Waist circumference · people with CKD who are overweight or obese
1 finding from 1 review
Proteinuria · people with CKD who are overweight or obese
1 finding from 1 review
Systolic blood pressure · people with CKD who are overweight or obese
1 finding from 1 review
Adverse events: number of people experiencing adverse events (all cause or COPD‐related), serious adverse events, mortality · COPD
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing adverse events (all… compared with control (low certainty).
1 finding from 1 review
Adherence to pharmacotherapy: number of people achieving adherence to medication · COPD
Multi‐component intervention may leads to higher adherence to pharmacotherapy: number of people achieving adherence… compared with control (low certainty).
1 finding from 1 review
Quality of life: SGRQ total, SF CRDQ total, CAT total · COPD
1 finding from 1 review
Hospital admissions · COPD
Multi‐component intervention may leads to lower hospital service utilisation: number of people admitted to hospital… compared with control (low certainty).
1 finding from 1 review
Exacerbations: number of people experiencing moderate or severe exacerbations · COPD
It is very uncertain whether multi‐component intervention changes exacerbations: number of people experiencing moderate or severe… compared with control (very low certainty).
1 finding from 1 review
Depression: meeting study criteria for depression at end of · people with depression after stroke
It is very uncertain whether pharmacological interventions changes depression: meeting study criteria for depression at end of… compared with placebo (very low certainty).
2 findings from 1 review
Depression: < 50% reduction in scale scores at end of treatment (primary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes depression: < 50% reduction in scale scores at end of treatment… compared with placebo (very low certainty).
1 finding from 1 review
Depression: mean scores at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: death (secondary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects (central nervous system) · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ central nervous system events (e.g. confusion,… compared with placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
It is very uncertain whether pharmacological interventions changes adverse events: all ‐ gastrointestinal effects (e.g. constipation,… compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
2778 participants
Low
Respiratory‐related hospital admissions · patients with chronic obstructive pulmonary disease
It is very uncertain whether self‐management interventions changes respiratory‐related hospital admissions compared with usual care (very low certainty).
OR 0.75 [0.57, 0.98]
3263 participants
Very low